TY - JOUR
T1 - Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients
AU - Xi, Yang
AU - Jingying, Dai
AU - Chenglong, Li
AU - Hong, Zheng
AU - Rong, Zhang
AU - Xiaodong, Wang
AU - Chunsen, Wang
AU - Xiaobing, Huang
N1 - Funding Information:
The authors thank all the doctors at the institute who participated in this study for providing the follow-up samples and information. Funding. This research was funded by the Applied Foundation Project of Sichuan Science and Technology Department (no. 2018JY0615) and the Doctor Foundation of Sichuan Provincial People's Hospital (no. 2015BS11).
Funding Information:
This research was funded by the Applied Foundation Project of Sichuan Science and Technology Department (no. 2018JY0615)
Publisher Copyright:
© Copyright © 2021 Xi, Jingying, Chenglong, Hong, Rong, Xiaodong, Chunsen and Xiaobing.
PY - 2021/8/24
Y1 - 2021/8/24
N2 - To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia). Twenty-four patients were enrolled in this observational study during April 2015 to May 2018. The most common adverse event was reversible CTCAE grade 2 thrombocytopenia (20/24). Strikingly, all 24 patients had response to this epigenetic regimen accompanied with decreased measurable residual disease. The overall survival rate is 79.2% (19/24), with a relapse-free survival rate of 79.2% (19/24). During this regimen treatment, Th1 cells and CD3+CD4-CD8+T cells increased, and Th17 cells decreased gradually. The status of high Th1 and low Th17 cells was still observed on the 3rd month after discontinuation of this regimen. Interestingly, the significantly elevated ratio of Th1/Th17 seemed to reflect the treatment-related immune effect, which may be a valuable marker to be monitored in the early-relapse stage for evaluating the efficacy and prognosis.
AB - To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia). Twenty-four patients were enrolled in this observational study during April 2015 to May 2018. The most common adverse event was reversible CTCAE grade 2 thrombocytopenia (20/24). Strikingly, all 24 patients had response to this epigenetic regimen accompanied with decreased measurable residual disease. The overall survival rate is 79.2% (19/24), with a relapse-free survival rate of 79.2% (19/24). During this regimen treatment, Th1 cells and CD3+CD4-CD8+T cells increased, and Th17 cells decreased gradually. The status of high Th1 and low Th17 cells was still observed on the 3rd month after discontinuation of this regimen. Interestingly, the significantly elevated ratio of Th1/Th17 seemed to reflect the treatment-related immune effect, which may be a valuable marker to be monitored in the early-relapse stage for evaluating the efficacy and prognosis.
UR - http://www.scopus.com/inward/record.url?scp=85114399524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114399524&partnerID=8YFLogxK
U2 - 10.3389/fmolb.2020.595395
DO - 10.3389/fmolb.2020.595395
M3 - Article
C2 - 34504867
AN - SCOPUS:85114399524
VL - 7
JO - Frontiers in Molecular Biosciences
JF - Frontiers in Molecular Biosciences
SN - 2296-889X
M1 - 595395
ER -